Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Breast 1

Conditions

Sarcoma, Ewing 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 624pembrolizumab 603Magnetic Resonance Spectroscopy 550Carboplatin 444Cisplatin 394Cyclophosphamide 392Biopsy 368Paclitaxel 320Nivolumab 320Gemcitabine 313Radiotherapy 279Bevacizumab 242Dexamethasone 220fludarabine 210Docetaxel 197durvalumab 192Oxaliplatin 184venetoclax 182atezolizumab 182Fluorouracil 174Rituximab 172Pemetrexed 171Capecitabine 167Doxorubicin 164Radiation 162Radiosurgery 156Ipilimumab 143Etoposide 142Leucovorin 140Lenalidomide 136

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × romiplostim × 90 days × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT07048249 2026-03-18

Single Arm Romiplostim to Prevent CIT

Children's Hospital Medical Center, Cincinnati

Phase EARLY_PHASE1 Recruiting
26 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡